Balyasny Asset Management L.P. Acquires 59,334 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Balyasny Asset Management L.P. boosted its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 277.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 80,743 shares of the company’s stock after buying an additional 59,334 shares during the quarter. Balyasny Asset Management L.P. owned approximately 0.14% of Ginkgo Bioworks worth $793,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new position in Ginkgo Bioworks during the fourth quarter valued at approximately $29,000. KBC Group NV purchased a new position in shares of Ginkgo Bioworks in the fourth quarter worth $31,000. KLP Kapitalforvaltning AS purchased a new position in shares of Ginkgo Bioworks in the fourth quarter worth $46,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Ginkgo Bioworks in the fourth quarter worth $116,000. Finally, Palumbo Wealth Management LLC purchased a new position in shares of Ginkgo Bioworks in the fourth quarter worth $144,000. 78.63% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Stock Performance

DNA stock opened at $7.79 on Thursday. Ginkgo Bioworks Holdings, Inc. has a one year low of $5.00 and a one year high of $37.26. The company’s fifty day moving average price is $7.14 and its 200-day moving average price is $9.07. The company has a market capitalization of $452.08 million, a PE ratio of -0.60 and a beta of 1.29.

Ginkgo Bioworks (NYSE:DNA) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. The business had revenue of $48.32 million for the quarter, compared to analysts’ expectations of $38.70 million. On average, research analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.